The local efficacy of I-131 for F-18 FDG PET positive lesions in patients with recurrent or metastatic thyroid carcinomas

Kotaro Yoshio, Shuhei Sato, Yoshihiro Okumura, Kuniaki Katsui, Mitsuhiro Takemoto, Etsuji Suzuki, Norihisa Katayama, Mitsumasa Kaji, Susumu Kanazawa

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Purpose: The aim of this study was to evaluate the local efficacy of I-131 for F-18 fluorodeoxyglucose positron emission tomography (FDG PET)-positive lesions. Methods: Whole-body FDG PET/CT was performed on 37 patients (55 cases: 16 men, 21 women; age range: 24-82 years; mean age ± standard deviation: 60.5 ± 16.0 years) with differentiated thyroid cancer after total thyroidectomy. The metastatic or recurrent lesions were divided into 5 categories: primary tumor bed, lymph node, lung, bone, and other. The well-defined lesions were measured on CT, and the sizes were compared before and after radioactive iodine therapy. Results: The analysis was performed on 37 patients with 44 lesions (lymph node:24, lung:16, bone:4). Sixteen lesions (70%) were increased and 7 (30%) showed no change or reduction when there was positive accumulation on FDG PET/CT and negative accumulation on I-131 (F(+)I(-)) group. In the positive accumulation for both FDG PET/CT and I-131 (F(+)I(+)) group, 5 lesions (63%) were increased and 3 (37%) showed no change or reduction. There was no significant difference for the tendency to increase in size between the F(+)I(-) and the F(+)I(+) groups. Conclusions: Lesions which show positive accumulations on FDG PET/CT have a greater tendency to increase in size. FDG-avid lesions are resistant to radioactive iodine therapy with or without I-131 uptake.

Original languageEnglish
Pages (from-to)113-117
Number of pages5
JournalClinical Nuclear Medicine
Volume36
Issue number2
DOIs
Publication statusPublished - Feb 2011

Fingerprint

Fluorodeoxyglucose F18
Thyroid Neoplasms
Positron-Emission Tomography
Iodine
Lymph Nodes
Bone and Bones
Lung
Thyroidectomy
Therapeutics
Neoplasms

Keywords

  • FDG PET/CT
  • I-131 scintigram
  • local efficacy
  • prognosis
  • thyroid cancer

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

The local efficacy of I-131 for F-18 FDG PET positive lesions in patients with recurrent or metastatic thyroid carcinomas. / Yoshio, Kotaro; Sato, Shuhei; Okumura, Yoshihiro; Katsui, Kuniaki; Takemoto, Mitsuhiro; Suzuki, Etsuji; Katayama, Norihisa; Kaji, Mitsumasa; Kanazawa, Susumu.

In: Clinical Nuclear Medicine, Vol. 36, No. 2, 02.2011, p. 113-117.

Research output: Contribution to journalArticle

@article{f9c7ddad731e427bb3eb42c4d3f57ca1,
title = "The local efficacy of I-131 for F-18 FDG PET positive lesions in patients with recurrent or metastatic thyroid carcinomas",
abstract = "Purpose: The aim of this study was to evaluate the local efficacy of I-131 for F-18 fluorodeoxyglucose positron emission tomography (FDG PET)-positive lesions. Methods: Whole-body FDG PET/CT was performed on 37 patients (55 cases: 16 men, 21 women; age range: 24-82 years; mean age ± standard deviation: 60.5 ± 16.0 years) with differentiated thyroid cancer after total thyroidectomy. The metastatic or recurrent lesions were divided into 5 categories: primary tumor bed, lymph node, lung, bone, and other. The well-defined lesions were measured on CT, and the sizes were compared before and after radioactive iodine therapy. Results: The analysis was performed on 37 patients with 44 lesions (lymph node:24, lung:16, bone:4). Sixteen lesions (70{\%}) were increased and 7 (30{\%}) showed no change or reduction when there was positive accumulation on FDG PET/CT and negative accumulation on I-131 (F(+)I(-)) group. In the positive accumulation for both FDG PET/CT and I-131 (F(+)I(+)) group, 5 lesions (63{\%}) were increased and 3 (37{\%}) showed no change or reduction. There was no significant difference for the tendency to increase in size between the F(+)I(-) and the F(+)I(+) groups. Conclusions: Lesions which show positive accumulations on FDG PET/CT have a greater tendency to increase in size. FDG-avid lesions are resistant to radioactive iodine therapy with or without I-131 uptake.",
keywords = "FDG PET/CT, I-131 scintigram, local efficacy, prognosis, thyroid cancer",
author = "Kotaro Yoshio and Shuhei Sato and Yoshihiro Okumura and Kuniaki Katsui and Mitsuhiro Takemoto and Etsuji Suzuki and Norihisa Katayama and Mitsumasa Kaji and Susumu Kanazawa",
year = "2011",
month = "2",
doi = "10.1097/RLU.0b013e318203bb6c",
language = "English",
volume = "36",
pages = "113--117",
journal = "Clinical Nuclear Medicine",
issn = "0363-9762",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - The local efficacy of I-131 for F-18 FDG PET positive lesions in patients with recurrent or metastatic thyroid carcinomas

AU - Yoshio, Kotaro

AU - Sato, Shuhei

AU - Okumura, Yoshihiro

AU - Katsui, Kuniaki

AU - Takemoto, Mitsuhiro

AU - Suzuki, Etsuji

AU - Katayama, Norihisa

AU - Kaji, Mitsumasa

AU - Kanazawa, Susumu

PY - 2011/2

Y1 - 2011/2

N2 - Purpose: The aim of this study was to evaluate the local efficacy of I-131 for F-18 fluorodeoxyglucose positron emission tomography (FDG PET)-positive lesions. Methods: Whole-body FDG PET/CT was performed on 37 patients (55 cases: 16 men, 21 women; age range: 24-82 years; mean age ± standard deviation: 60.5 ± 16.0 years) with differentiated thyroid cancer after total thyroidectomy. The metastatic or recurrent lesions were divided into 5 categories: primary tumor bed, lymph node, lung, bone, and other. The well-defined lesions were measured on CT, and the sizes were compared before and after radioactive iodine therapy. Results: The analysis was performed on 37 patients with 44 lesions (lymph node:24, lung:16, bone:4). Sixteen lesions (70%) were increased and 7 (30%) showed no change or reduction when there was positive accumulation on FDG PET/CT and negative accumulation on I-131 (F(+)I(-)) group. In the positive accumulation for both FDG PET/CT and I-131 (F(+)I(+)) group, 5 lesions (63%) were increased and 3 (37%) showed no change or reduction. There was no significant difference for the tendency to increase in size between the F(+)I(-) and the F(+)I(+) groups. Conclusions: Lesions which show positive accumulations on FDG PET/CT have a greater tendency to increase in size. FDG-avid lesions are resistant to radioactive iodine therapy with or without I-131 uptake.

AB - Purpose: The aim of this study was to evaluate the local efficacy of I-131 for F-18 fluorodeoxyglucose positron emission tomography (FDG PET)-positive lesions. Methods: Whole-body FDG PET/CT was performed on 37 patients (55 cases: 16 men, 21 women; age range: 24-82 years; mean age ± standard deviation: 60.5 ± 16.0 years) with differentiated thyroid cancer after total thyroidectomy. The metastatic or recurrent lesions were divided into 5 categories: primary tumor bed, lymph node, lung, bone, and other. The well-defined lesions were measured on CT, and the sizes were compared before and after radioactive iodine therapy. Results: The analysis was performed on 37 patients with 44 lesions (lymph node:24, lung:16, bone:4). Sixteen lesions (70%) were increased and 7 (30%) showed no change or reduction when there was positive accumulation on FDG PET/CT and negative accumulation on I-131 (F(+)I(-)) group. In the positive accumulation for both FDG PET/CT and I-131 (F(+)I(+)) group, 5 lesions (63%) were increased and 3 (37%) showed no change or reduction. There was no significant difference for the tendency to increase in size between the F(+)I(-) and the F(+)I(+) groups. Conclusions: Lesions which show positive accumulations on FDG PET/CT have a greater tendency to increase in size. FDG-avid lesions are resistant to radioactive iodine therapy with or without I-131 uptake.

KW - FDG PET/CT

KW - I-131 scintigram

KW - local efficacy

KW - prognosis

KW - thyroid cancer

UR - http://www.scopus.com/inward/record.url?scp=79551604849&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79551604849&partnerID=8YFLogxK

U2 - 10.1097/RLU.0b013e318203bb6c

DO - 10.1097/RLU.0b013e318203bb6c

M3 - Article

C2 - 21220972

AN - SCOPUS:79551604849

VL - 36

SP - 113

EP - 117

JO - Clinical Nuclear Medicine

JF - Clinical Nuclear Medicine

SN - 0363-9762

IS - 2

ER -